<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35105">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01843920</url>
  </required_header>
  <id_info>
    <org_study_id>11095 Gas Duration</org_study_id>
    <secondary_id>11-095</secondary_id>
    <nct_id>NCT01843920</nct_id>
  </id_info>
  <brief_title>The Effect of Glaucoma Drops on of the Duration of a Pure Intraocular Gas Bubble</brief_title>
  <official_title>A Prospective, Randomized Study Comparing the Effects of Topical Aqueous Suppressants on Intraocular Gas Duration Following Scleral Buckling and Pneumatic Retinopexy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brian Burke, MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A controlled clinical study comparing the effect of topical aqueous suppressants on
      intraocular gas duration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Prospective, Randomized Study Comparing the Effects of Topical Aqueous Suppressants on
      Intraocular Gas Duration following Scleral Buckling and Pneumatic Retinopexy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Complete resolution of intraocular gas bubble</measure>
    <time_frame>Following surgery, until gas bubble is gone. Up to 2 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>This will be reported by the patient when they see/feel the gas bubble disappear.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Return of intraocular pressure to normal levels</measure>
    <time_frame>Post-op Day 1, Week 1, Month 1, Month 2, Month 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>The normal intraocular pressure range is 10-21 mm Hg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Scleral Buckling</condition>
  <arm_group>
    <arm_group_label>Post surgery without glaucoma drops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This will be for the group that had gas duration surgery using SF6 (Sulfur Hexafluoride) or C3F8 (perfluoropropane gas tamponade)  and only uses the standard post-operative topical drops.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post surgery with glaucoma drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This will be for the group that had gas duration surgery (using SF6 or C3F8). In addition to the standard post-operative topical drops, glaucoma drops, Timolol-dorzolamide (timolol 0.5%-dorzolamide 2%) will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol-dorzolamide (Glaucoma drops)</intervention_name>
    <description>Patients will receive the standard post-operative drops regardless of what group you are in. The glaucoma drops will only be given to the experimental group.</description>
    <arm_group_label>Post surgery with glaucoma drops</arm_group_label>
    <other_name>timol</other_name>
    <other_name>glaucoma drops</other_name>
    <other_name>dorzolamide</other_name>
    <other_name>timol-dorzolamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard post-operative topical drops</intervention_name>
    <description>Patients will receive the standard post-operative drops regardless of what group ther are in. The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim</description>
    <arm_group_label>Post surgery without glaucoma drops</arm_group_label>
    <arm_group_label>Post surgery with glaucoma drops</arm_group_label>
    <other_name>glaucoma</other_name>
    <other_name>drops</other_name>
    <other_name>standard of care</other_name>
    <other_name>oral</other_name>
    <other_name>corticosteroid</other_name>
    <other_name>prednisolone</other_name>
    <other_name>Polymyxin B</other_name>
    <other_name>trimethoprim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study.

          -  Have undergone eye surgery including scleral buckling or pneumatic retinopexy for
             treatment of retinal detachment other condition at the discretion of the
             investigator.

        Exclusion Criteria:

          -  Prior surgery to treat glaucoma.

          -  Current use of glaucoma eye drops.

          -  Absence of a lens in the eye or presence of a lens implant in front of the iris
             (colored part of your eye).

          -  Allergy or contraindication to any of the glaucoma drops being used in this study
             (e.g., sulfa allergy, asthma, chronic obstructive pulmonary disease (bronchitis or
             emphysema), slow heart rate).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mid Atlantic Retina- Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 6, 2013</lastchanged_date>
  <firstreceived_date>April 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>Brian Burke, MPH</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>eye</keyword>
  <keyword>pneumatic retinopexy</keyword>
  <keyword>topical</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polymyxin B</mesh_term>
    <mesh_term>Polymyxins</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Dorzolamide</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
